EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Impact of Immunoglobulin Heavy Chain Clonality in Pediatric B‐Cell Precursor Acute Lymphoblastic Leukemia

Yuta Katai, Tatsuya Kamitori iD, Satoshi Saida iD, Yoshinori Uchihara, Ryo Akazawa, Kiyotaka Isobe, Takashi Mikami, Hirohito Kubota iD, Itaru Kato iD, Katsutsugu Umeda iD, Hiroo Ueno, Junko Takita

Cancer Medicine · 2025

DOI: 10.1002/cam4.71336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yuta Katai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Immunoglobulin Heavy Chains, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Foundation for Promotion of Cancer Research, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Recent advancements in risk stratification have greatly improved outcomes in pediatric B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). Despite favorable prognostic indicators, including the absence of cytogenetic abnormalities and minimal residual disease (MRD) negativity, relapse remains a major clinical concern. Methods and Results We investigated the clinical significance of immunoglobulin heavy chain (IGH) clonality using RNA sequencing data in BCP‐ALL. We analyzed IGH clonality from 136 patients. IGH abundance followed a power law distribution, which enabled us to identify disease clones as outliers based on read count. In total, 330 disease clones were detected, and patients were categorized into three clonotype groups: undetectable disease clone (UDC), incomplete disease clone (IDC), and complete disease clone (CDC). Clinical outcomes were compared across clonotypes, including in subgroups with high hyperdiploidy (HHD) and MRD negativity. Among patients with HHD, significant prognostic differences were observed across clonotypes (event‐free survival [EFS], p = 0.01; overall survival [OS], p = 0.08), even among those who were MRD‐negative (EFS, p = 0.01; OS, p = 0.03). Furthermore, comparisons of IGH sequences between diagnosis and relapse indicated that while initial disease clones often contributed to relapse, newly expanded clones frequently emerged, particularly in patients with HHD.

Conclusions

These findings highlight the importance of analyzing the IGH repertoire in refining risk stratification and underscore the need for advanced sequencing‐based MRD monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Heavy ChainsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansChildMaleFemaleChild, PreschoolNeoplasm, ResidualPrognosisAdolescentInfant

Stichwörter der Autor:innen

B‐cell lymphoblastic leukemiaIGH rearrangementclonalitypediatric leukemiaprognosis

Substanzen

Immunoglobulin Heavy Chains

Autor:innen und Institutionen

  • Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
  • Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
  • Department of Pediatric Oncology, National Cancer Center, Tokyo, Japan.

ORCID-Profile: Tatsuya Kamitori, Satoshi Saida, Hirohito Kubota, Itaru Kato, Katsutsugu Umeda

Förderung

  • Japan Agency for Medical Research and Development
  • Foundation for Promotion of Cancer Research
  • Takeda Science Foundation
  • Princess Takamatsu Cancer Research Fund
  • Japan Society for the Promotion of Science

Zitieren

APA

Katai, Y., Kamitori, T., Saida, S., Uchihara, Y., Akazawa, R., Isobe, K., Mikami, T., Kubota, H., Kato, I., Umeda, K., Ueno, H., & Takita, J. (2025). Clinical Impact of Immunoglobulin Heavy Chain Clonality in Pediatric B‐Cell Precursor Acute Lymphoblastic Leukemia. Cancer Medicine. https://doi.org/10.1002/cam4.71336

Vancouver

Katai Y, Kamitori T, Saida S, Uchihara Y, Akazawa R, Isobe K, et al. Clinical Impact of Immunoglobulin Heavy Chain Clonality in Pediatric B‐Cell Precursor Acute Lymphoblastic Leukemia. Cancer Medicine. 2025. doi:10.1002/cam4.71336

BibTeX
@article{Katai2025,
  author = {Katai, Yuta and Kamitori, Tatsuya and Saida, Satoshi and Uchihara, Yoshinori and Akazawa, Ryo and Isobe, Kiyotaka and Mikami, Takashi and Kubota, Hirohito and Kato, Itaru and Umeda, Katsutsugu and Ueno, Hiroo and Takita, Junko},
  title = {Clinical Impact of Immunoglobulin Heavy Chain Clonality in Pediatric B‐Cell Precursor Acute Lymphoblastic Leukemia},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71336}
}
Kostenlos starten →